Diabest Foundation walks for Inreda


November 8, 2016 – “Within a group, exploring your own limits and discovering your possiblities (and realizing your dreams) for people living with diabetes.”

This is what the Dutch foundation Diabest is stimulating. And this goal is achieved by organizing a yearly group expedition (organized for and by people living with diabetes): a hike in the Alps during which participants learn from each other and (re)discover themselves. After months of training in the Netherlands, this year’s group of participants (13 in total) headed hiking for 7 days through the Stubaier Höheweg in Austria from September 10 to September 18. During the hike, the group of participants was supported by a medical team from the St. Anna Ziekenhuis in Geldrop (NL).

Besides each participant’s personal journey, the foundation uses the event to raise funds for a general goal for all people with diabetes. For this years’s edition, the group had chosen to gather fund to sponsor the CE certification of the artificial pancreas of Inreda Diabetic.

As you may know, CE certification is needed to introduce any new medical device on the European market. And one of the main requirements for the CE is to have completed clinical studies. While we already completed one successful clinical study for the CE, we are eagerly preparing the second one. This second clinical study is organized together with the Academic Medical Center in Amsterdam and the Rijnstate hospital in Arnhem (NL) and will involve 24 adults with type 1 diabetes using our artificial pancreas for 2 weeks in a daily life situation.

All in all, the Diabest team has collected a total sum of € 4,880.50 which we will use to buy some of the materials and parts needed for the upcoming clinical study (infusion sets, sensors etc). We’d like to infinitely thank all participants and organizers of this year’s expedition, as well as everyone who donated to Diabest, and thus contributed to bring our artificial pancreas further on its CE journey. Thank you so much!



< Back to the news overview